Panobinostat and Ruxolitinib In MyElofibrosis (PRIME Trial)

Part of paid clinical trials in New York, New York.

Sponsor
John Mascarenhas
Study ID
NCT01693601
Phase
PHASE1/PHASE2
Status
Completed

Conditions

  • Myelofibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Panobinostat — DRUG
    PO TIW QOW or PO TIW QW
  • Ruxolitinib — DRUG
    PO BID x 28 days

Study Details

This is a single-center, single arm, dose finding study to assess safety and tolerability of the oral combination of Panobinostat and Ruxolitinib in patients with myelofibrosis (MF) in chronic and accelerated phase.

Key Dates

Start date
Jan 31, 2013
Status verified
Oct 2023
Primary completion
May 18, 2018
Completion
May 18, 2018

Study Design

Enrollment
15 participants (actual)
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT

Arms

  • Experimental: Panobinostat and Ruxolitinib
    Combination of Panobinostat and Ruxolitinib

Primary Outcome Measure

Number of Patients That Achieve Stable Disease or Clinical Improvement [ Time Frame: at least 6 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Icahn School of Medicine at Mount SinaiNew YorkNew York10029-

Find similar trials in New York, NY

By research site
Icahn School of Medicine at Mount Sinai· New York, NY

Related Studies